Neurometrix Inc (NASDAQ:NURO) has earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.
Zacks has also assigned Neurometrix an industry rank of 166 out of 265 based on the ratings given to its competitors.
Several analysts have issued reports on the company. ValuEngine raised Neurometrix from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Neurometrix from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th.
Shares of NASDAQ NURO opened at $1.40 on Wednesday. The firm has a market cap of $10.00, a price-to-earnings ratio of -0.12 and a beta of 0.25. Neurometrix has a 12-month low of $1.20 and a 12-month high of $5.84.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3337550/neurometrix-inc-nuro-receives-consensus-recommendation-of-hold-from-brokerages.html.
Neurometrix Company Profile
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.